Trifluoroacetic acid → (2S)-1-(4-Chlorophenyl)-4-(4-(isoquinolin-6-yl)-1H-pyrazol-1-yl)butan-2-amine
反応式
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C@H:9]([NH:27]C(=O)OC(C)(C)C)[CH2:10][CH2:11][N:12]2[CH:16]=[C:15]([C:17]3[CH:18]=[C:19]4[C:24](=[CH:25][CH:26]=3)[CH:23]=[N:22][CH:21]=[CH:20]4)[CH:14]=[N:13]2)=[CH:4][CH:3]=1.C(O)(C(F)(F)F)=O>C(Cl)Cl>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C@H:9]([NH2:27])[CH2:10][CH2:11][N:12]2[CH:16]=[C:15]([C:17]3[CH:18]=[C:19]4[C:24](=[CH:25][CH:26]=3)[CH:23]=[N:22][CH:21]=[CH:20]4)[CH:14]=[N:13]2)=[CH:4][CH:3]=1参加物
4
実験手順
A mixture of tert-butyl(S)-1-(4-chlorophenyl)-4-(4-(isoquinolin-6-yl)-1H-pyrazol-1-yl)butan-2-ylcarbamate (320 mg, 0.67 mmol) and TFA (5.00 mL, 64 mmol) in DCM (5 mL) was stirred at room temperature for 2 hours. After concentration by vacuum distillation, the residue was purified by reverse-phase HPLC (Phenomenex Synergi 4m Max RP 80 A column, 150×21 mm, 20 mL/min, 10-95% CH3CN/H2O, 0.1% TFA, 10.5 minute gradient) to give the product as an off-white solid (165 mg, 65%). HRMS (TOF) Calcd for C22H22ClN4+: 377.1535, found: 377.1531.
後処理
- concentrationAfter concentration
- distillationby vacuum distillation
- customthe residue was purified by reverse-phase HPLC (Phenomenex Synergi 4m Max RP 80 A column, 150×21 mm, 20 mL/min, 10-95% CH3CN/H2O, 0.1% TFA, 10.5 minute gradient)
出典と根拠
- ORDレコード
- ord-392744a0cc364195b71eba45d7f74473
- 出典データセット
- uspto-grants-2011_03
- 特許番号
- US07897619B2
反応ノート
読み込み中…